Shares of Isis Pharmaceuticals Inc. fell 31.9 percent after the company disclosed data from the first of two Phase III studies with Affinitak, showing the antisense drug partnered with Eli Lilly and Co. failed to meet its primary endpoint. (BioWorld Today)